Oral Agents in Cancer Treatment: The Context for Adherence

Seminars in Oncology Nursing

Volumn 27, Issue 2, 2011, Pages 104-115

  Barton, Debra ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Oral adherence; Oral agents; Side effects; Small molecules

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; HUMAN; NEOPLASM; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PATIENT COMPLIANCE;

EID: 79955043842     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2011.02.002     Document Type: Article

References (38)

1. Bonadonna G. Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 1989, 7:1380-1397.
2. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010, 73:156-166.
3. Janni W., Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010, 36:249-261.
4. Lonning P.E. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opin Invest Drugs 2010, 19(suppl 1):S19-S30.
5. Oncology Nursing Drug Handbook 2005, Jones and Bartlett, Sudbury, MA. G. Wilkes, M. Barton-Burke (Eds.).
6. Micromedex 1.0 Healthcare series. DrugPoint Summary [Web page]. 2010. Available at: Updated July 1, 2010. (accessed July 29, 2010). http://www.thomsonhc.com.
7. Schiff D., Wen P.Y., van den Bent M.J. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009, 6:596-603.
8. Cavaletti G., Frigeni B., Lanzani F., et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010, 46:479-494.
9. Ettinger D.S., Armstrong D.K., Barbour S., et al. Antiemesis. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009, 7:572-595.
10. Blijlevens N.M.A. Cytotoxic treatment-induced gastrointestinal symptoms. Curr Opin Supp Palliat Care 2007, 1:16-22.
11. Iop A., Manfredi A.M., Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 2004, 15:712-720.
12. Butt Z., Rosenbloom S.K., Abernethy A.P., et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 2008, 6:448-455.
13. Barsevick A.M., Whitmer K., Walker L. In their own words: using the common sense model to analyze patient descriptions of cancer-related fatigue. Oncol Nurs Forum 2001, 28:1363-1369.
14. Singh B.N., Malhotra B.K. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 2004, 43:1127-1156.
15. Ogu C.C., Max J.L. Drug interactions due to cytochrome P450. Proc Bayl Univ Med Cent 2000, 13:421-423.
16. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009, 69:1777-1798.
17. Michael M., Doherty M.M. Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 2005, 23:205-229.
18. de Jonge M.E., Huitema A.D., Holtkamp M.J., et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005, 56:370-378.
19. Kiani J., Imam S.Z. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 2007, 6:33.
20. Girennavar B., Jayaprakasha G.K., Patil B.S. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J Food Sci 2007, 72:C417-C421.
21. Kalyn R. Overview of targeted therapies in oncology. J Oncol Pharm Pract 2007, 13:199-205.
22. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007, 64(suppl 5):S4-S7.
23. Crean S., Boyd D.M., Sercus B., et al. Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature. Curr Drug Safety 2009, 4:143-154.
24. Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 2009, 35:733-737.
25. Maitland M.L., Bakris G.L., Black H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010, 102:596-604.
26. Schmidinger M., Zielinski C.C. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treat Rev 2009, 35:289-296.
27. Widakowich C., de Castro G., de Azambuja E., et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007, 12:1443-1455.
28. Kim A., Balis F.M., Widemann B.C. Sorafenib and sunitinib. Oncologist 2009, 14:800-805.
29. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
30. Torino F., Corsello S.M., Longo R., et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6:219-228.
31. Hu J.C., Sadeghi P., Pinter-Brown L.C., et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007, 56:317-326.
32. Wood L.S., Lemont H., Jatoi A., et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Commun Oncol 2010, 7:23-29.
33. Wagner L.I., Lacouture M.E. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology 2007, 21(suppl 5):34-36.
34. Iacovelli L. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective. Oncology 2007, 21(suppl 5):31-33.
35. Azad N.S., Aragon-Ching J.B., Dahut W.L., et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009, 15:1411-1416.
36. Lynch T.J., Kim E.S., Eaby B., et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007, 12:610-621.
37. Boere I.A., Hamberg P., Sleijfer S. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Sci 2010, 101:7-15.
38. LaCouture M.E., Wu S., Robert C., et al. Evolving strategies for the management of hand-foot skin reaction associated with multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13:1001-1011.